ClinicalTrials.gg
RecruitingNCT07223398Updated Oct 20, 2026

Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)

An interventional study of Standard PN and Patient Choice in Substance Use Disorders, sponsored by Yale University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 20, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Substance-Related Disorders by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · Yale University.

Planned enrollment
12th of 59
400 · median 74
Started
2025
the only one that year
No phase
32 of 63
4 open now
Registered
61st of 63
by date

Among the 63 studies in Substance-Related Disorders by Yale University, this one is the 12th largest by planned enrollment of the 59 interventional ones that give a count, is the only one that started in 2025, is one of 32 with no phase, and was the 61st registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 63 studies in Substance-Related Disorders by Yale University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Substance-Related Disorders by Yale University, or all of them as a file.
02

Study summary

This study seeks to compare the effectiveness of two Patient Navigation models of care to evaluate the proportion who initiate PrEP/ART and substance use/substance use disorder (SU/SUD) treatment. A standardized Patient Navigation (PN) arm will be compared with a shared decision-making model in the form of Patient Choice (PC) through the offer of a menu of existing community-based health service delivery options. This design will offer providers, correctional and public health authorities, payers and policy makers' timely and relevant data to assess the effectiveness of Patient Navigation and Patient Choice models of care as potentially useful re-entry and relapse prevention treatment options.

Read the detailed description

This study will be done in two phases. Aim 1, the R61 portion of the project will be a Pilot Study, and Aim 2, the R33 portion of the project will be a Randomized Controlled Trail informed by the pilot.

The focus of this registration is Aim 2, the randomized controlled trial. The Aim 1 (R61) portion is registered with NCT06439329. In Aim 2 (R33), investigators will evaluate standard PN compared to PN+PC on participant outcomes, implementation outcomes and costs associated with implementing the study.

03

Conditions studied

  • Substance Use Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to provide written in English or Spanish;
  • living in the community of Western, CT, Dallas and Tarrant Counties in TX and Madison County, KY (potential for Fayette county as well);
  • Those with current justice involvement (with in the past 12 months) (e.g., prison, jail, community supervision);
  • willing to have testing to determine negative or positive status;
  • persons with HIV who report not currently taking ART in past 6 months OR persons who test negative for HIV who report not taking PrEP that have a PrEP indication in past 12 months, including (i) condomless sexual intercourse; and/or (ii) sharing IDU equipment with HIV positive or unknown status partner; and/or (iii) bacterial STI and;
  • Having a history of opioid and/or stimulant use in the last 12 months within the community.

Exclusion criteria

Exclusion Criteria:

  • severe medical or psychiatric disability making participation unsafe;
  • unable to provide consent.
  • persons self-reporting pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Standard Patient Navigation (PN)

    PNs are "near-peer" professionals who have shared lived experiences with participants and help them overcome barriers to accessing and engaging in quality care. PNs are trained and linked to PrEP/ART and SUD services. This manualized PN approach provides a complete assessment of participant needs, goal setting, and help with appointment scheduling.

    Behavioral: Standard PN

  • Experimental
    PN + Patient Choice (PC) (PN+PC)

    PNs working in the PN + PC arm will be trained to engage participants in selecting from a menu of service options in their community. This menu of SUD and HIV prevention and treatment service delivery options will be created through bolstering and working with our Community Advisory Boards (CAB). PNs will also be trained to discuss sexual and substance use history with participants in order to provide education and motivation towards starting PrEP/ART and SUD treatment.

    Behavioral: Standard PN · Behavioral: Patient Choice

Interventions

  • BehavioralStandard PN

    Standard of care

  • BehavioralPatient Choice

    Participants can select from a menu of options including brick and mortar services, Mobile Health Unit (MHU) or telehealth services.

06

What researchers measure

Primary outcomes

  1. Percentage of participants who initiate or re-initiate PrEP

    Percentage of participants not living with HIV who initiate or re-initiate PrEP within the 6-month intervention period by self report

    Time frame: 6 months

  2. Percentage of participants who initiate or re-initiate ART

    Percentage of participants living with HIV who initiate or re-initiate ART within the 6-month intervention period by self report

    Time frame: 6 months

Secondary outcomes

  1. Percentage of participants that adhere to PrEP

    Percentage of participants that adhere to PrEP

    Time frame: 6 and 12 months

  2. Percentage of participants retaining on PrEP

    Percentage of participants retaining on PrEP

    Time frame: 6 and 12 months

  3. HIV incidence

    HIV incidence \[binary\] for those testing negative using rapid point of care (POC) test over time

    Time frame: 6 and 12 months

  4. Percentage of participants that adhere to ART

    Percentage of participants that adhere to ART

    Time frame: 6 and 12 months

  5. ART retention

    For persons living with HIV (PLH), ART retention \[binary\]

    Time frame: 6 and 12 months

  6. Substance use treatment

    Percentage of participants engaged in substance use disorder (SUD) treatment

    Time frame: 6 and 12 months

  7. HIV viral suppression

    For PLH, HIV viral suppression, for those with HIV at time of randomization: the percent who maintain or achieve HIV viral load \< 200 copies/mL at 6 months

    Time frame: 6 months

  8. Retention in HIV PrEP/ART

    Retention in HIV PrEP/ART care \[binary\]: defined as attending 2 or more visits in 6-months

    Time frame: 6 months

  9. Number of Participants Who Had Any Needle Sharing Activity to Assess HIV Risk Behavior

    Number of Participants Who Had Any Needle Sharing Activity

    Time frame: 6 and 12 months

  10. Number of Participants Who Had Sex Without a Condom to assess HIV Risk Behavior

    Number of Participants Who Had Vaginal or Anal Sex Without a Condom

    Time frame: 6 and 12 months

  11. Days of using opioids

    Measured by Timeline Followback, which assesses self-reported alcohol and other drug use including opioid use

    Time frame: 6 and 12 months

  12. Number of participants with with overdose events

    Number of participants with non-fatal and fatal overdose events

    Time frame: 6 and 12 months

  13. Percentage of participants with retention in SUD treatment

    Retention in SUD treatment including but not exclusive to Medication for Opioid Use Disorder (MOUD) for Opioid Use Disorder (OUD)

    Time frame: 6 and 12 months

  14. Quality of Life assessed using PROMIS-PROPr

    PROMIS-PROPr assesses general societal health. Total summary score ranges from -0.022, worse than dead, to 1, perfect health.

    Time frame: 6 and 12 months

  15. Change in Depression assessed using Patient Health Questionnaire-9 (PHQ-9)

    Depression will be assessed using the PHQ-9. PHQ-9 is a 9-item validated questionnaire used to screen for depression with a range of scores from 0-45. A cumulative score of ≥10 is considered positive with lower scores indicating no or mild anxiety.

    Time frame: 6 and 12 months

  16. Recidivism: Reasons

    Number of participants per reason for arrest/ incarceration/return-to-custody

    Time frame: 6 and 12 months

  17. Recidivism: Mean days in custody/incarcerated

    Mean days in custody/incarcerated

    Time frame: 6 and 12 months

  18. Recidivism: Mean days to return

    Mean days to return to custody/incarcerated

    Time frame: 6 and 12 months

  19. HIV and SU Stigma assessed using Substance Use Stigma Mechanisms Scale (SU-SMS)

    Mean score for Enacted (6 items), Anticipated (6 items), and Internalized (6 items) scales. Each scale is scored 1-5, with higher scores indicating greater endorsement of substance use stigma

    Time frame: 6 and 12 months

  20. Percentage of participants diagnosed with SUD

    Percentage of participants diagnosed with SUD using DSM-5

    Time frame: Baseline and 12 months

07

Study locations

4 of 4 sites recruiting
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
    Recruiting
    • Sandy Springer, MD · Principal investigator
  • College of Medicine at the University of Kentucky
    Lexington, Kentucky 40506, United States
    Recruiting
    • Michele Staton, PhD, MSW · Principal investigator
  • University of Texas Southwestern Medical Center (UTSW)
    Dallas, Texas 75390, United States
    Recruiting
    • Ank Nijhawan, MD, MPH · Principal investigator
  • Texas Christian University's (TCU) School of Medicine
    Fort Worth, Texas 76109, United States
    Recruiting
    • Kevin Knight,, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 25 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Oct 31, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 1, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: •••6680→•••2454. See the current contact
Oct 20, 2026
Show all 2 updates
  1. Oct 20, 2026
    Contact Study contact's phone or email changed: •••6680→•••2454. See the current contact
    + 1 other change: verification date
  2. Sep 29, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07223398
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Nov 24, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Sandra Springer, MD
Contact
Sandra.springer@yale.edu
203-231-2454
Alysse Schultheis, MA
Contact
alysse.schultheis@yale.edu
203-231-2454
Sandra Springer, MD
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion